Deutsch
A A A
DE
Bereichsnavigation

Previous
RHÖN-KLINIKUM AG | 08/08/2024

First half of 2024: RHÖN-KLINIKUM AG continues good business performance – outlook confirmed

RHÖN-KLINIKUM AG closed the first half of 2024 with a 6.5% increase in revenues to 775.5 million euros (H1 2023: 728.2 million euros). Despite a challenging market environment, consolidated profit increased by 68.9% to reach EUR 20.6 million (H1 2023: EUR 12.2 million). From January to June 2024 a total of 463,111 patients were treated on an inpatient and outpatient basis in the Group’s hospitals and medical care centres, 3.8% more compared with the same period of the previous year (H1 2023: 446,022).

At 49.1 million euros, EBITDA was above the previous year’s level (H1 2023: 45.2 million euros). Materials and consumables used increased as a result of higher purchasing prices and the provision of material costintensive services to 266.2 million euros (H1 2023: 237.0 million euros).

“RHÖN-KLINIKUM AG is a sound, efficient and economically responsible company. Our five hospital sites in the federal states of Bavaria, Brandenburg, Hesse and Thuringia are first-class, highly specialised facilities which continue to show a solid performance. We therefore see ourselves well prepared for the impending healthcare reform”, said Prof Dr. Tobias Kaltenbach, chairman of the Board of Management of RHÖN-KLINIKUM AG.

Outlook for 2024 confirmed

For the current financial year, RHÖN-KLINIKUM AG continues to expect revenues of 1.6 billion euros within a range of plus or minus 5%. For earnings before interest, tax and depreciation/amortisation (EBITDA), a level of between 110 million euros and 120 million euros is expected.

The outlook is subject to considerable uncertainties in connection with the numerous global crises in the form of inflation and price increases and any regulatory measures impacting our remuneration structure in 2024. The 2024 Half-Year Report is published on the Internet.


Contact:

RHÖN-KLINIKUM AG | Head of Corporate Finance, Treasury, Investor Relations and Sustainability
Julian Schmitt | T. +49 9771 65-12250 | julian.schmitt@rhoen-klinikum-ag.com